Nature Reviews Cardiology (2016) https://doi.org/10.1038/nrcardio.2015.206 Published online 04 January 2016
In the version of this article initially published online and in print, the following competing interests were not declared. M.T. declares that he is consultant for 4Tech, Abbott Vascular and Boston Scientific; has received personal fees from CoreMedic, Edwards Lifesciences, Mitraltech and SwissVortex; and is a shareholder of 4Tech. F.M. declares that he has received grants and/or research support from Abbott, Biotronik, Boston Scientific, Edwards Lifesciences, Medtronic, NVT and Terumo; has received consulting fees and/or honoraria from Abbott, Cardiovalve (Mitraltech), Edwards Lifesciences, Magenta, Medtronic, Perifect, SwissVortex, Transseptal Solutions and Xeltis; has received royalty income and/or intellectual property rights from Edwards Lifesciences; and is a shareholder of 4Tech, Cardiogard, Magenta, Occlufit, Perifect, SwissVortex and Transseptal Solutions.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Taramasso, M., Maisano, F. Author Correction: Functional mitral regurgitation: should all valves be replaced?. Nat Rev Cardiol 17, 828 (2020). https://doi.org/10.1038/s41569-020-0415-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41569-020-0415-7